153 related articles for article (PubMed ID: 2505272)
1. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W
Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
[No Abstract] [Full Text] [Related]
2. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
Witjes WP; van der Meijden PM; Roos EP; Witjes JA; Steerenberg PA; Doesburg W; Debruyne FM
Prog Clin Biol Res; 1992; 378():59-67. PubMed ID: 1301587
[No Abstract] [Full Text] [Related]
3. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
Rintala E; Jauhiainen K; Alfthan O
Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270
[No Abstract] [Full Text] [Related]
4. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
Debruyne FM; van der Meijden AP; Franssen MP
Prog Clin Biol Res; 1989; 303():435-46. PubMed ID: 2506556
[No Abstract] [Full Text] [Related]
5. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
[No Abstract] [Full Text] [Related]
6. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial.
DeBruyne FM; van der Meijden AP; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg JJ
Urology; 1988 Mar; 31(3 Suppl):20-5. PubMed ID: 3279698
[TBL] [Abstract][Full Text] [Related]
7. BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
Fisher HA
Prog Clin Biol Res; 1989; 310():275-83. PubMed ID: 2505271
[No Abstract] [Full Text] [Related]
8. Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer.
Jauhiainen K; Rintala E; Kaasinen E; Ruutu M; Alfthan O
Arch Esp Urol; 1990; 43 Suppl 2():159-64. PubMed ID: 2129004
[TBL] [Abstract][Full Text] [Related]
9. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.
Lamm DL; Crissmann J; Blumenstein B; Crawford ED; Montie J; Scardino P; Grossman HB; Stanisic T; Smith J; Sullivan J
Prog Clin Biol Res; 1989; 310():263-70. PubMed ID: 2672016
[No Abstract] [Full Text] [Related]
10. Multicenter study of the BCG Tokyo strain for intravesical treatment in patients with superficial bladder cancer. BCG Study Group.
Aso Y; Akaza H; Kameyama S; Niijima T
Prog Clin Biol Res; 1989; 303():383-91. PubMed ID: 2675000
[No Abstract] [Full Text] [Related]
11. [Mitomycin C in the topical treatment of superficial neoplasms of the bladder].
Milani C; Bassi PF; Meneghini A; Giunta A; Tejerizo JC; dal Bianco M; Zattoni F; Garbeglio A
Arch Esp Urol; 1989 Oct; 42(8):761-7. PubMed ID: 2515812
[TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.
Catalona WJ; Ratliff TL
Surg Annu; 1990; 22():363-78. PubMed ID: 2408170
[No Abstract] [Full Text] [Related]
13. BCG in the management of superficial bladder cancer.
Guinan P; Richardson C; Hanna M; Rubenstein M
Prog Clin Biol Res; 1989; 303():447-53. PubMed ID: 2675002
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder.
Reitsma DJ; Guinan P; Lamm DL; Khanna OP; Brosma SA; DeKernion JB; Williams RD; Sipmson G; Hanna MG
Prog Clin Biol Res; 1989; 310():171-85. PubMed ID: 2672014
[No Abstract] [Full Text] [Related]
15. Introduction and overview of intravesical therapy for superficial bladder cancer.
Soloway MS
Urology; 1988 Mar; 31(3 Suppl):5-16. PubMed ID: 3126593
[TBL] [Abstract][Full Text] [Related]
16. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.
Pinsky CM; Camacho FJ; Kerr D; Geller NL; Klein FA; Herr HA; Whitmore WF; Oettgen HF
Cancer Treat Rep; 1985 Jan; 69(1):47-53. PubMed ID: 3881177
[TBL] [Abstract][Full Text] [Related]
17. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
Brosman S
Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
[No Abstract] [Full Text] [Related]
18. Superficial bladder disease: case studies and therapeutic advances.
Soloway MS; Droller MJ; Flanigan RC; Nseyo UO
Urology; 1992 Dec; 40(6 Suppl):11-22. PubMed ID: 1466118
[No Abstract] [Full Text] [Related]
19. BCG therapy of superficial bladder tumors.
Herr HW
Prog Clin Biol Res; 1989; 303():369-74. PubMed ID: 2674999
[No Abstract] [Full Text] [Related]
20. [Treatment of superficial tumors of the bladder with bacillus Calmette-Guérin].
Ackermann D; Schnyder M; Bandelier D; Studer UE
J Urol (Paris); 1986; 92(1):33-8. PubMed ID: 3722851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
